Insider Selling: Guardant Health (NASDAQ:GH) Director Sells $142,785.00 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,500 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $95.19, for a total value of $142,785.00. Following the completion of the transaction, the director owned 815 shares of the company’s stock, valued at $77,579.85. The trade was a 64.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Friday, September 12th, Medina Manuel Hidalgo sold 2,165 shares of Guardant Health stock. The shares were sold at an average price of $54.16, for a total value of $117,256.40.

Guardant Health Price Performance

NASDAQ:GH opened at $97.84 on Thursday. The company has a market capitalization of $12.33 billion, a price-to-earnings ratio of -30.48 and a beta of 1.56. The business has a 50 day moving average of $69.41 and a 200 day moving average of $56.11. Guardant Health, Inc. has a 1-year low of $28.45 and a 1-year high of $101.57.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, October 29th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.26). The business had revenue of $265.20 million for the quarter, compared to analysts’ expectations of $235.72 million. The business’s quarterly revenue was up 38.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.88) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Hedge Funds Weigh In On Guardant Health

Several hedge funds have recently made changes to their positions in the business. TD Waterhouse Canada Inc. lifted its stake in Guardant Health by 3.2% in the third quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company’s stock worth $306,000 after acquiring an additional 151 shares during the period. Signaturefd LLC raised its holdings in Guardant Health by 50.5% in the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after purchasing an additional 213 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Guardant Health by 0.3% in the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock worth $4,439,000 after purchasing an additional 282 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Guardant Health by 8.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,016 shares of the company’s stock valued at $251,000 after purchasing an additional 307 shares in the last quarter. Finally, IFP Advisors Inc increased its position in shares of Guardant Health by 120.1% during the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after buying an additional 334 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Leerink Partners upped their price target on shares of Guardant Health from $70.00 to $75.00 and gave the company an “outperform” rating in a research report on Thursday, September 25th. Scotiabank increased their target price on Guardant Health from $57.00 to $60.00 and gave the company a “sector outperform” rating in a report on Thursday, July 31st. Cowen restated a “buy” rating on shares of Guardant Health in a research report on Thursday, October 30th. Wolfe Research upgraded Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price objective for the company in a research report on Thursday, September 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a report on Wednesday, October 8th. Twenty-three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $77.14.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.